Cargando…
Small molecule receptor tyrosine kinase inhibitor of platelet-derived growth factor signaling (SU9518) modifies radiation response in fibroblasts and endothelial cells
BACKGROUND: Several small receptor tyrosine kinase inhibitors (RTKI) have entered clinical cancer trials alone and in combination with radiotherapy or chemotherapy. The inhibitory spectrum of these compounds is often not restricted to a single target. For example Imatinib/Gleevec (primarily a bcr/ab...
Autores principales: | Li, Minglun, Ping, Gong, Plathow, Christian, Trinh, Thuy, Lipson, Kenneth E, Hauser, Kai, Krempien, Robert, Debus, Juergen, Abdollahi, Amir, Huber, Peter E |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1458351/ https://www.ncbi.nlm.nih.gov/pubmed/16556328 http://dx.doi.org/10.1186/1471-2407-6-79 |
Ejemplares similares
-
Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis
por: Abdollahi, Amir, et al.
Publicado: (2005) -
Cetuximab, gemcitabine and radiotherapy in locally advanced pancreatic cancer: Long-term results of the randomized controlled phase II PARC trial
por: Liermann, Jakob, et al.
Publicado: (2022) -
Late treatment with imatinib mesylate ameliorates radiation-induced lung fibrosis in a mouse model
por: Li, Minglun, et al.
Publicado: (2009) -
Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo
por: Klenke, Frank M, et al.
Publicado: (2007) -
Intraoperative Electron Radiation Therapy (IOERT) in the management of locally recurrent rectal cancer
por: Roeder, Falk, et al.
Publicado: (2012)